Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer

Catalent has reached an agreement to acquire Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market.

Read The Wall Street Journal’s coverage of the deal.

Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals

Catalent will undertake the commercial manufacturing and packaging of Phathom Pharmaceuticals’ lead compound, vonoprazan, a novel, orally active-potassium competitive acid blocker (P-CAB), at its large -scale oral solid dose manufacturing site in Winchester, Kentucky.

Catalent in the News

Catalent’s Chair and CEO, John Chiminski Interviewed by Fox Business Network

John Chiminski, Catalent's Chair and CEO, discussed manufacturing COVID-19 vaccines for Moderna, Johnson & Johnson and AstraZeneca. He describes how Catalent overcame supply chain challenges at the height of the pandemic. Watch the clip.

Catalent has been awarded more than 80 COVID-19-related compounds, and is on track to deliver over one billion COVID-19 vaccine and treatment doses this year. 

Growth of mRNA Discussed by Catalent Experts in Pharma Manufacturing

Catalent’s Matt Blume, Vice President of Business Transformation in Clinical Supply Services and Stacey Treichler, Ph.D., Associate Director of Marketing, Biotherapeutics, discuss the growth of one of the industry’s most talked about innovations, mRNA technology.

Catalent Expert Discusses Dosage Form Design in Pharmaceutical Technology

William Chin, Ph.D., Catalent’s Global Scientific Affairs Manager, discusses the ways dosage form priorities are shifting to focus on user-friendliness in Pharmaceutical Technology.

Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs

AAPS 2021 PharmSci 360 | Philadelphia | October 17 – 20
Meet with Catalent experts in Philadelphia! Lisa Caralli, Director of Science & Technology, Catalent, will present “Strategies to Optimize the Dose Design Process to Create Better Treatments”.

PODD: Partnership Opportunities in Drug Delivery | Boston | October 28 – 29
Cornell Stamoran, Ph.D., Vice President, Strategy and Government Affairs, will moderate "Meeting the Formulation and Delivery Needs of Special Patient Populations: Focus on Pediatrics and Geriatrics".

Biologics

BPI East | Boston | September 20 - 23
Meet with Catalent Biologics experts at BPI East in our booth 808. Aaron Almeida, Manager, Manufacturing Process Optimization, Catalent Biologics, will present “Evaluation of a Next-Generation Downstream Approach to Improve Overall Manufacturing Process Intensity”. Register today.

World ADC San Diego Digital | Virtual Conference | October 11-14
Connect with Catalent at the World ADC San Diego digital conference. Yun Kim, Director, Protein Science, Catalent will present “Catalent’s SMARTag^® Technology: Enabling Precision ADC Development”.

Interphex | New York | October 19-21
Meet with Catalent Biologics experts at Interphex in our booth 1152. Learn more about our latest capacity expansions and technology enhancements for process development and clinical and commercial scale drug substance manufacturing.

BIO-Europe Digital | Virtual | October 25-28
Register now and connect with our Catalent Biologics experts over this 4-day virtual event.

Biologics Contract Manufacturing Europe | Virtual | October 27-28
Catalent is a proud sponsor of this year’s event. Register now and schedule a meeting with our experts to learn more about our capabilities in Europe and beyond.

Cell & Gene Therapy

Cell & Gene Therapy Manufacturing and Commercialization | Boston | September 20 - 23
Join us on September 21, 2021, to hear Catalent expert, Nagendra Singh, Senior Scientist, Downstream Process Development, Catalent Cell & Gene Therapy, give an insightful presentation titled, “Evaluation of Novel Affinity Resin with Alkali Stable Ligand for AAV Viral Vectors”.

Knowledge for Growth | Ghent, Belgium | September 27 – 29

Within the “Personalized Medicine” track, Dr. Pinxteren will join the “Beyond the Science” panel session on Tuesday, 28^th September at 3:30 p.m. CET.

Cell Gene Meeting on the Mesa | Carlsbad, California & Virtual | October 12-14
Meet Catalent’s Cell & Gene Therapy team online in our virtual booth at Meeting on the Mesa. Schedule a meeting to discuss your current or future AAV, CAR-T, lentiviral or other advanced therapeutic projects and learn how our expertise can help bring your lifechanging treatment to patients.

Clinical Supply Services

GCSG 2021 European Virtual Knowledge Forum | Virtual | October 5-7
Catalent is delighted to be sponsoring and exhibiting at this year’s event. Our experts will be available to connect and participate in networking events throughout the course of this forum. Learn more and schedule a meeting with our team today!

Consumer Health

Webinar | The Growth of Premium in Nutritional Supplements | September 27

Experts discuss several new advanced delivery technologies that can help differentiate your premium supplement as you look to continue your brand’s growth.

Webinar | How Unit Dose Beauty Is Reshaping the Beauty Market | September 30
When it comes to certain ingredients and types of beauty products, conserving the potency is key to keeping products at their full potential. As we think of how the beauty market has evolved and started adopting to new trends, there is a huge opportunity for unit dose delivery systems, such as capsules and ampoules, to accelerate beyond the high success it has today.

Vitafoods Europe | Geneva, Switzerland | October 5-7
Learn more about Catalent’s development and manufacturing capabilities for consumer health products, including about our proposed acquisition of Bettera. Schedule a meeting with our experts or drop in on our booth E103 at Vitafoods Europe.

SupplySide West | Las Vegas | October 25-28
Visit Catalent’s experts in booth 2839. Schedule a meeting to learn more about our move into the growing market for gummies as well as other latest product offerings in the consumer health space.

Oral Drug Delivery

Webinar | Scale Up & Tech Transfer of Fluid-Bed Coating Processes | September 21
This webinar will summarize the principles of top-spray and bottom-spray coating using the fluidized bed platform, and will then discuss ways of selecting the most appropriate technique to meet the target product profile. Experts will also cover the scale up approach of multiparticulate coating using the fluid-bed platform as a strategy to achieve a modified release drug product.

Cannabinoid-Derived Pharmaceuticals Summit | Boston | September 21 - 23
Want to learn more about our latest developments and capabilities in oral technologies and manufacturing? Connect with our Catalent experts in Boston who will be available to assist you with your next challenge.  David Fulper, Ph.D., Director, Science & Technology, Catalent will present “Exploring the Oral Delivery of Cannabinoids: Challenges, Approaches, and Solutions”. 

European Paediatric Formulation Initiative (EuPFI) | Virtual | September 22 - 23
Catalent is excited to participate at this year’s EuPFI 2021. Register now and visit our virtual booth or schedule a meeting with our experts to learn more about Catalent’s latest innovations in oral technologies.

Webinar | A Guide to Drug Development of Challenging Molecules | September 23
Experts will discuss some of the key considerations, strategies, and solutions available in the drug development of challenging molecules.

Making Pharmaceuticals UK | Coventry, U.K. | October 5-6

Matt Ling, Ph.D., Director of Scientific Services, Catalent will present “Overcoming Key Challenges in Early Oral Formulation Development”

Webinar | Concept to Dosing: Challenges in New Orphan Drugs | October 6
A group of experienced cancer drug developers to discuss key strategies in managing an orphan drug program. Matthew Mollan, Ph.D., Regional Head of Operations at Catalent, will review the developability challenges of orphan oncology drugs and provide recommendations for innovator companies to consider in order to avoid common pitfalls during scale-up.

Webinar | Maintaining Drug Product Properties and Optimizing Late-Stage Manufacturing Efficiency | October 14
Register for this webinar to hear experts share approaches on how to minimize burdens often faced in the transition from early phase to late phase of a small molecule program.

Webinar | Highly Potent API Drug Product Development and Manufacturing Using Micronization Technology | October 12
This webinar will discuss how to classify HPAPIs in early development and share recommendations for safe product handling, from clinical manufacturing to commercialization.

A Catalyst in Drug Development

Elaine Villalobos
Supervisor Technical Services, Sorocaba, Brazil

In her role at Catalent, Ms. Villalobos relentlessly develops her technical services team in Sorocaba and Indaiatuba to be more agile at transferring and maintaining reliable manufacturing processes. She has a wide range of experience in dosage forms in softgels, creams and tablets. Learn a little more about Ms. Villalobos’ role and discover some of her techniques for troubleshooting tech transfers and the ways her team helps drive Catalent’s ‘Patient First’ mission.

Top Content

Cell & Gene Therapy

●      Executive Summary: “Formulation Strategies for AAV-Based Gene Therapies”  - Understand the formulation development considerations for viral vectors, and how to apply to them the knowledge gained from protein formulation development. 

●      Article: “Overcoming the Raw Material Hurdle: Plasmids for Viral Vector-Based Gene Therapies” - Understand the importance of having access to high-quality pDNA throughout the development and manufacturing process and the benefits of a single supplier for both pDNA and viral vectors. 

●      Executive Summary: “Readiness through Planning and Alignment: Guiding Gene Therapies from Clinic to Market” - Learn how integrated service providers can streamline manufacturing, development, and commercialization for optimal regulatory and process outcomes for gene therapy programs. 

Oral Drug Delivery

●     Whitepaper: “Selecting the Most Suitable Dosage Form Technology for the Oral Delivery of Lipid-Based Formulations” -  Learn how the target product profile, technical limitations, and phase of development can impact lipid-based drug delivery system choice. 

●      Webinar: “Reducing Inhalation Burden Through High-Dose, Carrier-Free Spray Dry Powders” - This webinar explores how spray-dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to regions of the deep lung, providing an alternative approach to large, porous particles. 

●      Case Study: “Improving Bioavailability using PBPK Modeling & Parallel Formulation Screening”  - A team of bioavailability experts used OptiForm^® Solution Suite, Catalent’s proprietary bioavailability enhancement platform, to optimize and develop Phase 1 clinical formulation within a short timeline 

●      Survey: “Exclusive Orphan Drugs Industry Survey Results Desire to Treat Rare Diseases Tempered by a Lack of Internal Expertise and Capability” - In an August 2020 survey of nearly 600 qualified respondents from the orphan drugs space, Catalent explored the driving forces and challenges in developing and commercializing drugs with orphan designation. 

Virtual Site Tours

 Biologics Development and Manufacturing

• Explore the world-class late-stage and commercial manufacturing for vial fill/finish and secondary packaging of biologics and sterile products in this 360° virtual tour of Catalent’s facility in Anagni, Italy.

Consumer Health

• In this 360° virtual tour, explore our facility in Windsor, Ontario, one of two sites located in Canada offering softgel development and manufacturing capabilities for the Pharmaceutical and Consumer Health industries.

Oral Development and Manufacturing

• In this 360° virtual tour explore the capabilities located at Catalent’s Winchester, Kentucky, facility, home to Catalent’s flagship U.S. manufacturing location for large scale complex-controlled release oral dose forms.

We are the Catalyst for your success. Join us!

Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and across Europe.

Visit  www.catalent.com/careers for more information.

Every brand has a challenge. We have a solution.

or call +1 877 891 9609 to speak with one of our experts today!

To unsubscribe or manage your subscriptions, please click here.

For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers.

Catalent Pharma Solutions respects your privacy.

Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content.

© 2021, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved.